DigitStorm 2018
Friday, August 7, 2026
21.1
C
Bengaluru
Hot topics
Are Indian Pharma Business Leaders Adopting Digital Transformation?
We will need to find a way to bring together the capabilities of the Medical Rep, the changed scenario of the visit and the ways we can reach doctors into one single strategy rather than looking at the physical and the digital parts separately. Our medical reps will continue to be the core of our promotion, and our digital strategy will need to empower them to not only do a better call but also support their efforts by building processes that will help them beyond the few minutes that they spend in the Clinic. Marketing budgets will have to move away from conventional investments and also think beyond hardware to increase digital engagement.
IMS Health Market Reflection Report for June 2016
Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of different companies, brands and therapy areas in the Indian Pharmaceutical Market.
DiME (Digi MarketEr):-TiME to SHiNE
The new sparkling DIME (Digi MarketEr) are the ones who embrace digital transformation with open arms and voraciously feed on data analytics to satisfy their performance outcomes with an informed business decision. The benefit of being DIME is that it propels data management out of the hands of individual stakeholders, and puts data sets with insights on to center glass table (Transparent workplace) for informed decision making.
Interview with Ajit Singh, Chairman, ACG
Special interview with the Chairman of ACG and an invitation to "Pharmaceutical Marketing in the New Age" - a conference presented by ACG in partnership with MedicinMan
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Hot topics
Frontline Managers
Articles by Vivek Hattangadi, Raja Reddy, K. Hariram, Satish Kota, P. S. Parameswaran, Gopal Kishore, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal and Mahendra Kumar Rai
Great Opportunity for Pharma People to Listen to What Doctors have to Say
An insightful and informative Q&A session with Dr. Tejal...
Finding the middle ground for Doctor-Stakeholder Relationship
Healthcare systems around the world differ – public, private or a mix of both public and private (like in India). With all the variance in healthcare delivery models, the risks to healthcare professionals remain universal: needle injuries to litigations to episodes of threats/ violence
Medical Reps will Remain – What will be their Future Role?
There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it?
“Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s.
The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest.
“Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.
Indian Pharma Competitor Analysis – Jan 2025
Competitor Analysis – Indian Pharma Market Jan 2025
This analysis...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
Newsletter
Get important news delivered directly to your inbox and stay connected!